- Home
- SI vs SAVA Comparison
SI vs SAVA Comparison
Compare SI & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SI
- SAVA
- Stock Information
- Founded
- SI 2009
- SAVA 1998
- Country
- SI United States
- SAVA United States
- Employees
- SI N/A
- SAVA N/A
- Industry
- SI Medical/Dental Instruments
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- SI Health Care
- SAVA Health Care
- Exchange
- SI Nasdaq
- SAVA Nasdaq
- Market Cap
- SI 248.2M
- SAVA 213.0M
- IPO Year
- SI 2025
- SAVA N/A
- Fundamental
- Price
- SI $11.72
- SAVA $3.26
- Analyst Decision
- SI Strong Buy
- SAVA Buy
- Analyst Count
- SI 5
- SAVA 2
- Target Price
- SI $19.60
- SAVA $5.00
- AVG Volume (30 Days)
- SI 50.3K
- SAVA 2.6M
- Earning Date
- SI 11-11-2025
- SAVA 11-07-2025
- Dividend Yield
- SI N/A
- SAVA N/A
- EPS Growth
- SI N/A
- SAVA N/A
- EPS
- SI N/A
- SAVA N/A
- Revenue
- SI $37,324,000.00
- SAVA N/A
- Revenue This Year
- SI $40.62
- SAVA N/A
- Revenue Next Year
- SI $33.40
- SAVA N/A
- P/E Ratio
- SI N/A
- SAVA N/A
- Revenue Growth
- SI 64.07
- SAVA N/A
- 52 Week Low
- SI $11.51
- SAVA $1.15
- 52 Week High
- SI $17.94
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- SI N/A
- SAVA 43.43
- Support Level
- SI N/A
- SAVA $3.62
- Resistance Level
- SI N/A
- SAVA $4.01
- Average True Range (ATR)
- SI 0.00
- SAVA 0.34
- MACD
- SI 0.00
- SAVA -0.16
- Stochastic Oscillator
- SI 0.00
- SAVA 8.02
About SI Shoulder Innovations Inc. Common Stock
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.